AstraZeneca and Inserm collaborate on diabetes, CKD; Cynvenio raises $25.5M;

@FierceBiotech: ICYMI yesterday: Synergy soars on stellar constipation data, rekindling buyout chatter. Article | Follow @FierceBiotech

@JohnCFierce: BioMarin shines as dwarfism drug boosts growth in children. News | Follow @JohnCFierce

@DamianFierce: ICYMI: And hey $AGN's spending $2.1B on $KYTH and its chin-fat-reducing injection. Article | Follow @DamianFierce

> AstraZeneca ($AZN) and the French National Institute of Health and Medical Research (Inserm) have struck a deal to collaborate on new research related to diabetes and chronic kidney disease. Story

> Cynvenio Biosystems, which bills itself as a pioneer in LiquidBiopsy technology for the genomic analysis of tumor cells from whole blood, has garnered $25.5 million in a Series B. Release

Medical Device News

@FierceMedDev: FDA approves Roche's companion diagnostic for Pfizer's non-small cell lung cancer med. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI: HeartWare, hit with its fifth Class 1 recall of 2015, will replace defective blood pump controllers. Report | Follow @VarunSaxena2

@EmilyWFierce: Shire, Sanofi and Bayer have the best public reps in pharma. FiercePharma report | Follow @EmilyWFierce

> After 2014 IPO and recent take-out rumor, medical laser player Lumenis to be acquired for $510M. Story

> Medtronic buys into Arsenal, gets option to purchase the post-surgical foam startup subsidiary. Article

Pharma News

@FiercePharma: Vets and pharma execs gather in DC to trade notes on pets in cancer research. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Valeant said to step up talks on potential $800M deal for Egypt's Amoun. Report | Follow @CarlyHFierce

> Novartis zeroes in on costs as blockbusters-to-be Cosentyx, Entresto rev up. Report

> Zoetis knocks off 165 NJ jobs in Ackman-forced cost squeeze. News

> Merck inks $5.9M settlement to wrap up AzaSite off-label investigation. Article

Vaccines News

> Merck, GSK, Sanofi and Pfizer will vie for crown in tight vaccines race by 2020: Report. More

> When it comes to a MERS vaccine, for Big Pharma, the money's not there yet. More

> Merck, Sanofi granted European Commission thumbs-up on Gardasil 9. Story

> Ebola vaccines left hanging as GSK, Merck, J&J scramble for trial volunteers. Article

> Move over, India--China can make WHO-approved vaccines, too. Report

CRO News

> Quintiles beefs up its risk-based monitoring tech. Report

> Veristat reaches into the Bay Area with new outpost. Item

> AMRI recruits PerkinElmer to build out a new R&D hub. Article

> GVK inks a deep biotech deal as it rebuilds its reputation. News

> PPD partners up for real-world outcomes research. Story

Pharma Manufacturing News

> Sun purges 18 Ranbaxy execs in integration move. Item

> Geri-Care buiding second plant in Mississippi. More

> Lonza building viral therapies plant in Texas. News

> Thermo Fisher putting $22M into new plant in Scotland. Article

> Ukraine drugmaker opens $40M plant in Kyiv. Report

Pharma Asia News

> A heavier China drives cardio, diabetes and healthcare reforms. Item

> India's Strides-Shasun merger hits roadblock over shareholding structure. More

> China FDA ahead for UCB's Neupro after PhIII Parkinson's results. Story

> Emerging markets, Advair generic the trick as India's Cipla eyes growth. Article

> Researchers say compound stops transmission of malaria parasite in mice. Report

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.